Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CG Oncology, Inc.

Get SEC filing alerts via email and in your feed for CG Oncology, Inc.

CGON

CG Oncology, Inc.

About CG Oncology, Inc.

CG Oncology, Inc. is a clinical-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. Its primary focus is on non-muscle invasive bladder cancer (NMIBC), especially high-risk patients unresponsive to standard BCG therapy. Cretostimogene is designed as a bladder-sparing, intravesical treatment with potential for monotherapy and combination use, targeting durable complete responses and improved safety compared to existing options.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CG Oncology, Inc.

1
1
CG Oncology, Inc. CG Oncology Reports $1.1 Million Revenue and $60.2 Million Net Loss in Q1 2026

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
CG Oncology, Inc. CG Oncology Reports $161M Net Loss and $4M Revenue in Annual 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CG Oncology, Inc. CG Oncology Reports $1.7 Million Revenue and $119.7 Million Net Loss for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CG Oncology, Inc. CG Oncology Reports Significant Revenue Decline and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CG Oncology, Inc. CG Oncology Reports 90% Revenue Decline and 84% Increase in Operating Expenses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CG Oncology, Inc. CG Oncology Reports $88M Net Loss for 2024, Revenue Increases to $1.1M

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CG Oncology, Inc. CG Oncology Reports Significant Financial Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments